New research suggests that hypertension and diabetes and the use of medications to treat these conditions may influence the survival of ovarian cancer patients.
PARP inhibitors are an active, novel, and exciting class of anticancer agents. They have shown clear patient benefit in gBRCA, HR-deficient, and other ovarian cancers.
The use of cediranib as concurrent treatment with chemotherapy and as maintenance therapy in relapsed ovarian cancer was not associated with declines in quality of life.
The FDA announced the approval of niraparib, an oral PARP inhibitor, for the treatment of recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer.
A novel compound known as PM01183 showed promising activity in a two-stage phase II trial of women with platinum-resistant/refractory ovarian cancer.
The addition of the immune therapy motolimod to pegylated liposomal doxorubicin failed to improve overall survival among women with recurrent epithelial ovarian carcinoma in a randomized phase II trial.
A long-term phase III trial found that maintenance chemotherapy did not improve overall survival over surveillance among women with advanced ovarian/fallopian tube/peritoneal cancer who had a complete response to first-line therapy.
In this interview we discuss the idea behind an enhanced recovery program for patients undergoing cytoreductive surgery for ovarian cancer, as well as some of the potential cost savings.
Molecular expression analysis found that high-grade serous ovarian carcinomas exhibit significant alterations to cell cycle genes, DNA damage genes, and other pathways following treatment with neoadjuvant chemotherapy.
Event-free survival was not maintained in children and adolescents with intermediate-risk malignant germ cell tumors when cisplatin-based chemotherapy was reduced from four to three cycles and compressed from 5 to 3 days per cycles.